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Background: With the development of laparoscopic instruments such as the morcellator, a large number
of gynecologists have performed laparoscopic myomectomies. In this study, we reviewed all cases in
which residual myomas were identiﬁed by follow-up magnetic resonance imaging in order to evaluate
why any myomas would remain after a laparoscopic myomectomy and to ﬁnd their most common
location and depth within the uterus.
Methods: Patients (n ¼ 128) with uterine myomas who underwent a laparoscopic myomectomy between
2008 and 2011 and received follow-up magnetic resonance imaging 3 months afterward were reviewed
retrospectively. We analyzed the inﬂuence of preoperative gonadotrophin-releasing hormone agonist
treatment, as well as the location and depth of the residual myomas within the uterus. The pregnancy
rate in all cases was also investigated.
Results: The duration of the preoperative administration of gonadotrophin-releasing hormone agonist
was statistically longer in cases where multiple residual myomas were found, compared with cases
where a single residual myoma was present. There was no statistical difference in the rate and size of the
residual myomas among ﬁve different locations within the uterus. The rate of residual subserosal my-
omas was lowest, compared with two other types, and was statistically lower than residual intramus-
cular myomas (p < 0.05). The pregnancy rate in cases of residual myomas revealed no statistical
difference compared with nonresidual cases.
Conclusion: Because the completion of laparoscopic myomectomy without any residual myomas is
difﬁcult, informed consent regarding the possibility of their occurrence is necessary, regardless of the
number of myomas detected preoperatively. Moreover, intramuscular residual myomas should be given
particular attention due to their higher rate of incidence.
Copyright © 2015, The Asia-Paciﬁc Association for Gynecologic Endoscopy and Minimally Invasive
Therapy. Published by Elsevier Taiwan LLC. All rights reserved.Introduction
Laparoscopic myomectomy (LM) has been drawing more
attention recently, as it is a less invasive and more cosmetically
favored treatment.1 With the development of laparoscopic in-
struments such as the morcellator, a large number of gynecologists
have used this method to remove myomas.2 Because LM requires
advanced technical skill and sufﬁcient experience on the surgeon'sf interest with any author.
and Gynecology, Osaka Med-
8686, Japan.
ita).
for Gynecologic Endoscopy and Minimpart, it is still the subject of substantial controversy.2 Reconstructive
suturing and uterine wound healing are the two main problems
encountered with this operation, and a variety of case reports have
described spontaneous uterine rupture during pregnancy after
LM.3
Moreover, abdominal ultrasound transducers have been used
intra-abdominally for women undergoing myomectomies,
providing precise location and guidance to prevent residual my-
omas. Laparoscopic ultrasound transducers, however, are not
widely used, thus leading to a loss of feel during laparoscopy, and
this may also contribute to the occurrence of residual myomas after
LM.4
Until now there have been no reports concerning residual my-
omas following LM. In order to evaluate why they would remainally Invasive Therapy. Published by Elsevier Taiwan LLC. All rights reserved.
Table 2






Preoperative GnRHa treatment 52 (84) 56 (85) >0.05
Duration (mo) 3.5 ± 1.1 3.3 ± 1.2 >0.05
No. of residual cases 5 (8) 29 (44) <0.001
Data are presented as n (%) or mean ± SD.
GnRHa ¼ gonadotrophin-releasing hormone agonist.
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the uterus, we reviewed all cases where residual myomas were
identiﬁed by follow-up magnetic resonance imaging (MRI).
Materials and methods
Participants
Cases (n¼ 128) of uterinemyoma, between 2008 and 2011, were
retrospectively reviewed. We carried out an observation cohort
study. In all cases, preoperative MRI was given at the ﬁrst exami-
nation, and follow-up MRI was carried out 3 months after the
operation as a general rule. All patients hoped for future fecundity
and complained of symptoms such as menorrhagia and infertility.
In the infertile patients, LM was carried out when a hysteroscopy
conﬁrmed the presence of a deviated uterine cavity due to myoma.
Pregnant or menopausal patients were not included in this study.
Our institutional review board approved this protocol (No. 72) and
its consent form, and we received informed consent for this study
from all participants.
Laparoscopic technique and follow-up
All patients underwent a preoperative MRI to determine the
location and depth of the myoma. The LM was carried out by
making a small incision in the navel throughwhich the laparoscope
was inserted. Two or three small, additional incisions were made in
the abdomen, and other instruments were inserted through them.
Following a local injection of vasopressin, the myomawas removed
with a morcellator, and the incisions stitched using PDS-II Vicryl
(ETHICON, New Brunswick, New Jersey, US).
We resected all myomas conﬁrmed by the preoperative MRI to
be  1 cm. Three months after the LM, all patients underwent a
follow-up MRI to conﬁrm the healing of the sutured site. In this
study, we conﬁrmed the diagnosis of residual myoma when a
myoma >1 cm was identiﬁed by the follow-up MRI.
Statistical analysis
Comparisons between the two nonparametric groups were
performed with the nonparametric ManneWhitney U test or
parametric unpaired t test or the Chi-square test. The Pearson
correlation coefﬁcient was carried out for normally distributed




Of the 128 patients retrospectively studied, residual myomas
were identiﬁed in 34 patients (26.5%). There was no statistical
difference in the ratio of the chief complaints such as desire for a
baby, menorrhagia and abdominal distension between the residual
and nonresidual groups (Table 1).Table 1
Chief complaints.
Residual n ¼ 34 Nonresidual n ¼ 94 p
Desire for a baby 19 38 >0.05
Dysmenorrhea 13 46 >0.05
Abdominal distension 3 1 >0.05
No symptom 6 0 >0.05
There is overlap.The inﬂuence of preoperative gonadotrophin-releasing hormone
agonist treatment on residual myomas
The duration of preoperative administration of gonadotrophin-
releasing hormone agonist (GnRHa) showed no statistical differ-
ence between cases of single and multiple myomas; however, the
rate of residualmyomawas substantially higher in cases of multiple
myomas than in cases of single myoma (p < 0.05; Table 2). In
evaluating the effect of GnRHa, patients treated preoperativelywith
GnRHa showed no statistical difference in the rate of residual my-
oma when compared with those without preoperative treatment
(Table 3).
Regardless of the preoperative diagnosis of a single myoma, a
residual myomawas detected in three cases (Table 4). In Patient 1, a
small undetectable myoma of 1 cmwas adjacent to a large myoma;
therefore, a diagnosis of a single myoma was preoperatively made
(Fig. 1). In Patients 2 and 3, a preoperative MRI could not detect
multiple myomas and, therefore, any residual myomas were not
found until a follow-up MRI was carried out. In Patients 1 and 2, in
particular, GnRHa was administered for 3 months and 4 months,
respectively, before the operation in order to reduce the size of the
myoma.
The location and depth of residual myomas
There were no statistical differences in the rate and size of the
residual myomas among the ﬁve locations within the uterus
(Table 5). However, when classiﬁed into three locations, such as the
cervix, corpus, and fundus, cervical myomas had a higher tendency
to remain, as compared with corpus and fundal myomas (p < 0.05;
Table 5). Concerning depth, the residual rate of subserosal myomas
was lowest, compared with the other two types, and was statisti-
cally lower than intramuscular myomas (p < 0.05; Table 6).
Pregnancy rate following operation
Of the 128 patients who were involved in this study, 57 were
receiving treatment for infertility. The pregnancy rate of infertile
patients with residual myoma revealed no statistical difference
compared with those without residual myoma (Table 7).
Discussion
The recurrence of myomas has been reported to be higher after
laparoscopic procedures when compared with the openTable 3






Number of cases of residual myoma 30 (28) 4 (20) >0.05
Duration of administration 3.4 ± 1.2 d
Preoperative counts 2.9 ± 2.8 2.1 ± 2.0 >0.05
Residual myoma 1.7 ± 1.2 1.2 ± 1.0 >0.05
Data are presented as n (%) or mean ± SD.
GnRHa ¼ gonadotrophin-releasing hormone agonist.
Table 4
Detail if residual cases in which preoperative diagnosis was single myoma.
Case Chief complaints Duration of GnRHa (mo) Size (cm) Depth Location Residual size
1 Abdominal distention 3 7 Intra muscle Anterior 1.0
2 Dysmenorrhea 4 4 Subserosa Posterior 1.5
3 No symptom 0 3 Intra muscle Posterior 1.0
GnRHa ¼ gonadotrophin-releasing hormone agonist.
Fig. 1. (A) Small myoma of about 1 cm was not identiﬁed in preoperative myoma because it was adjacent to a large myoma. (B) Small myoma was ﬁrstly detected at postoperative
magnetic resonance imaging.
Table 5
The location of residual myomas.
Cervix Corpus Fundus p
Cervix anterior n ¼ 5 Cervix posterior n ¼ 4 Corpus anterior n ¼ 150 Corpus posterior n ¼ 118 Fundus n ¼ 69
Size of residual myoma (cm) 1.3 ± 0.3 3.015 ± 0.1 1.7 ± 0.6 1.6 ± 0.7 1.4 ± 0.3 >0.05
No. of residual myomas 2 (40) 2 (50) 25 (17) 20 (17) 6 (9) >0.05
Table 6
The depth of residual myomas.
Submucous n ¼ 24 Intramuscle n ¼ 248 Subserosa
n ¼ 74
p
Size of residual myoma (cm) 1.6 ± 0.1 1.7 ± 0.5 1.0 ± 1.0 >0.05
Postoperative counts of residual myomas (%) 2 (8%) 51 (20%) 2 (3%) <0.05
Table 7
Postoperative pregnancy rate of infertile patient.
Residual Nonresidual p
No. of cases (%) 19 (33.3%) 29 (50.8%) <0.05
Age (y) 32.3 ± 2.8 33.5 ± 3.7 >0.05
No of pregnant cases (%) 6 (31.6%) 11 (28.9%) >0.05
Data are presented as n (%) or mean ± SD.
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reported so far. For the ﬁrst time, this study examines residual
myomas following LM to evaluate the effectiveness of the
technique.
We determined the number of myomas to remove by preoper-
ative MRI; however, this study revealed the limitations of MRI toconﬁrm the correct number of myomas preoperatively. In this
study, there were three cases of residual myomas, even when a
single myoma diagnosis was made. In these cases, there were two
patterns of residual myomas: (1) a residual myoma so close to a
larger myoma that it is found for the ﬁrst time by postoperative
MRI; or (2) a myoma is found at a different location after the
operation due to the improvement of the deviation following LM.
In general, an LM, is a safe and reliable surgical procedure,5 but it
is not suitable in cases of large cervical myomas.6 Myomectomy for
cervical myomas is problematic because cervical myomas are very
close to neighboring structures, such as ureters, uterine arteries,
bladder, and rectum. Therefore, advanced laparoscopic technique is
necessary to remove cervical myomas completely, in comparison
with the removal of other types of myoma.7 This might be one of
the reasons why cervical myomas tend to remain at the site.
Y. Funauchi et al. / Gynecology and Minimally Invasive Therapy 4 (2015) 91e9494Subserosal myomas can be easily detected macroscopically
during surgery; therefore, their residual rate was statistically lower
in comparison with intramural and subserosal myomas in this
study. This is due to the inability to palpate a deeper lesion during
laparoscopy. During a laparotomy, the surgeon can touch and detect
the myoma, and an appropriate incision can be secured. Small
myomas which are not identiﬁed by laparoscopy, and which could
have been detected and removed through a laparotomy, may in-
crease the residual rate following LM. However, even in cases of
laparoscopic assisted myomectomy (LAM), residual myomas were
identiﬁed in six out of 14 cases (data not shown). Becausewe do not
have data on follow-up MRIs after abdominal myomectomy,
whether myomas remain more frequently after LM, compared with
laparoscopic assisted myomectomy (LAM) and abdominal myo-
mectomy, remains unknown. Conﬁrming the presence of residual
myomas during LM by reviewing preoperative MRI results alone is
insufﬁcient. We tried to ﬁnd residual myomas by transvaginal
scanning intraoperatively; however, the high echoic region
following myomectomy disturbed the detection of residual my-
omas. Therefore, residual myomas were identiﬁed in about half of
cases of multiple myomas (43.9%) in this study. However, in this
study, with the exception of one residual cervical myoma
measuring 3 cm, all other myomas were around 1.5 cm (Table 5),
which would probably not be clinically signiﬁcant.
Recently, intraoperative ultrasound has been used in a number
of nongynecologic surgeries, such as for the resection of the liver,
breast, colon, thyroid cancers, vascular surgeries, and minimally
invasive neurosurgery.8,9 A laparoscopic ultrasound transducer can
also be used during LM to isolate or identify smaller myomas if
necessary.9
Studies have evaluated the utility of preoperative treatment
with GnRHa before myomectomy10e12 and concluded that it may
increase not only the difﬁculty of myomectomy but also the like-
lihood of recurrent/persistent myomas.13 The American Society for
Reproductive Medicine has recommended that preoperative med-
ical treatment with GnRHa agonist should be considered for both
women who are anemic and those who might be candidates for a
less invasive procedure if the size of their myoma is moderately
smaller.14 If the size of the uterus exceeds the navel height, GnRHa
is administered for no less than a few months in order to secure an
operative site for laparoscopy.
Until now, the inﬂuence of residual myomas on fertility has not
been evaluated. In this study, 31.6% of infertile patients who hadresidual myomas became pregnant within 2 years after LM.
Therefore, we have concluded that, in cases where themainmyoma
is removed, such as those that distort the uterine cavity, residual
myomas might not have a negative effect on future fertility.
In conclusion, because the completion of LM without any re-
sidual myomas is difﬁcult, informed consent regarding the possi-
bility of their occurrence is necessary, regardless of the number of
myomas detected preoperatively. Moreover, intramuscular residual
myomas should be given particular attention due to their higher
rate of incidence.References
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